#USA #Bridgewater #Insmed #ARIKAYCE #Brinsupri

Insmed to Present Important Data at ERS Congress 2026

Insmed Incorporated, a leading biopharmaceutical company focused on developing innovative therapies for serious diseases, is set to reveal essential data from its respiratory portfolio at the upcoming European Respiratory Society (ERS) Congress 2026, taking place from September 5 to 9 in Barcelona, Spain. This event marks a significant opportunity for Insmed to share its advances in treating respiratory illnesses.

Among the highlights will be a late-breaking abstract from the Phase 3b ENCORE study, which explores the efficacy of ARIKAYCE® (amikacin liposome inhalation suspension) when used in conjunction with multidrug therapy for patients newly diagnosed with Mycobacterium avium complex (MAC) lung infections. This groundbreaking study showcases a 12-month treatment analysis that provides critical insights into its safety and overall effectiveness in managing this challenging condition.

In addition to ARIKAYCE, Insmed will also present findings related to other significant therapies in its pipeline, including research on BRINSUPRI® (brensocatib), which is the only approved treatment for non-cystic fibrosis bronchiectasis (NCFB). One of the key presentations will focus on a post hoc analysis of data assessing treatment patterns and healthcare resource utilization associated with bronchiectasis. This will help illuminate the psychosocial burden faced by patients suffering from this debilitating disease.

Dr. Martina Flammer, Chief Medical Officer at Insmed, expressed her enthusiasm about the forthcoming presentations. She noted, "These findings represent our unwavering commitment to advancing research that improves outcomes for patients with serious respiratory diseases. The Phase 3b ENCORE study significantly contributes to the understanding of recurrence rates following treatment for NTM lung disease, a critical issue for long-term patient management. Our comprehensive data portfolio aims to address the needs of patients who have historically faced limited treatment options and sheds light on the path forward in respiratory healthcare."

What to Expect at the ERS Congress

At the ERS Congress, Insmed's presentations are scheduled as follows:

• - Oral Session OA1207: Sunday, September 6, from 9:30 to 10:45 CEST, featuring a late-breaking abstract on microbiologic outcomes in patients newly diagnosed with MAC lung disease.
• - Poster Session PA908: Sunday, September 6, from 8:00 to 9:30 CEST, focusing on the post hoc analysis of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension.
• - Poster Session PA1839: Sunday, September 6, showcasing data on brensocatib in patients with NCFB and history of NTM infection.
• - Poster Session PA1840: A study quantifying the psychosocial impact of exacerbations in bronchiectasis, presented on September 6.
• - Poster Session PA2883: Monday, September 7, discussing treatment patterns and healthcare resource utilization related to bronchiectasis and pulmonary exacerbations in Spain.

About ARIKAYCE and Its Implementation

ARIKAYCE has been approved in the U.S. and Europe as a novel inhalation treatment for MAC lung disease, providing an innovative approach to delivery via Insmed's proprietary PULMOVANCE™ liposomal technology. Administered using the Lamira® Nebulizer System, it represents a significant advancement over traditional intravenous therapies that posed severe risks to patients.

In tandem, BRINSUPRI operates as a new oral therapy targeting chronic airway inflammation in NCFB patients. This drug exemplifies Insmed's mission to develop best-in-class therapies that meet pressing needs in respiratory care.

Conclusion

Insmed's upcoming presentations at the ERS Congress 2026 are expected to advance conversations around respiratory health and offer new hopes for patients impacted by these severe conditions. As the company shares its clinical and treatment data, both healthcare professionals and patients will gain valuable insights into the evolving landscape of respiratory therapy, emphasizing Insmed's role in leading the charge towards comprehensive care solutions for pulmonary diseases.

About Insmed
Insmed is globally recognized for its people-first approach, focusing on patients who encounter serious medical conditions. With headquarters in Bridgewater, New Jersey, and various research locations worldwide, Insmed’s ongoing commitment to groundbreaking therapies continues to earn it accolades as a top employer in the biopharmaceutical sector. To discover more about Insmed, visit Insmed's website or follow them on LinkedIn, Instagram, YouTube, and X.